A reliable rapid functional lab test to help in diagnosing heparin-induced thrombocytopenia (HIT) in daily practice

Recently brought under the spotlights because of the Astra-Zeneca anti-COVID 19 vaccine-associated thrombosis, HIT is a potentially life-threatening complication of treatment with anticoagulant heparin whose diagnostic work-up is still an issue.

An article recently published in Biomedicines reported the performance of a rapid flow cytometry-based assay (FCA) as being like the performance of the Gold Standard (Serotonin Release Assay: SRA) and whose optimization led to the development of HIT Confirm® which may possibly help in diagnosing HIT on the frontline.

FCA results were standardized according to the Heparin Platelet Activation (HEPLA) index which interestingly reflects the heparin-dependent immune-mediated mechanism of HIT. Based on the final HIT diagnosis established by expert opinion adjudication, the sensitivity and specificity of the FCA were 88 and 95%, respectively, values very similar to those of the SRA (88 and 97%, respectively).

Full article here: Biomedicines | Free Full-Text | Functional Flow Cytometric Assay for Reliable and Convenient Heparin-Induced Thrombocytopenia Diagnosis in Daily Practice (mdpi.com)